News Quantified

MRKR – marker therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Marker Therapeutics, Inc. (NASDAQ: MRKR) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $12.50 price target on the stock.

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference [Yahoo! Finance]

Form 8-K Marker Therapeutics, For: Mar 31

Form 10-K Marker Therapeutics, For: Dec 31

Form 8-K Marker Therapeutics, For: Mar 21

Form 8-K/A Marker Therapeutics, For: Feb 12

Form 8-K Marker Therapeutics, For: Feb 12

Top News Gainers

4/29 Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia 15.8%

8/15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs 15.0%

8/6 Marker Therapeutics Appoints Steve Elms to its Board of Directors 12.4%

4/10 FDA grants emergency authorization to two blood purification systems [MarketWatch] 10.9%

6/20 Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma 9.0%

5/9 Q1/2019 3/31/2019 EPS -0.120 ZacksConsensus N/A ActVsEst N/A - N/A 7.5%

3/2 Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million 6.7%

11/11 Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019 5.0%

8/8 Form 4 Marker Therapeutics, For: Aug 06 Filed by: ELMS STEVE 4.5%

8/13 TapImmune Inc. (NASDAQ: MRKR) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $16.00 price target on the stock. 4.4%

Top News Decliners

11/12 Form 10-Q Marker Therapeutics, For: Sep 30 -29.7%

7/19 Form 8-K Marker Therapeutics, For: Jul 19 -19.0%

3/12 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -16.8%

5/2 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. -8.2%

10/9 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth [Yahoo! Finance News] -6.5%

7/20 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR -5.8%

4/28 TapImmune Inc. (NASDAQ: MRKR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.7%

2/5 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.3%

2/11 Form 8-K Marker Therapeutics, For: Feb 11 -5.0%

4/21 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day